Blackmores Limited operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Blackmores Limited with three other
pharmaceutical manufacturers in Australasia:
Auscann Group Holdings Ltd
(2019
sales of 861,770.00 Australian Dollars [US$592,690.94 ]
),
ECS Botanics Holdings Ltd
(1,384.00 Australian Dollars [US$951.86 ]
), and
Immuron Limited
(2.92 million Australian Dollars [US$2.01 million]
of which 82%
was HyperImmune Products).
Sales Analysis.
Blackmores Limited reported sales of A$609.50 million (US$419.19 million)
for the
fiscal
year ending
June of 2019.
This
represents
a very small
increase of 1.4%
versus 2018, when the company's sales were A$601.14 million.